title: Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload.
abstract: Atrial (ANP) and brain (BNP) natriuretic peptides are hormones of myocardial cell origin. These hormones bind to the natriuretic peptide A receptor (NPRA) throughout the body, stimulating cGMP production and playing a key role in blood pressure control. Because NPRA receptors are present on cardiomyocytes, we hypothesized that natriuretic peptides may have direct autocrine or paracrine effects on cardiomyocytes or adjacent cardiac cells. Because both natriuretic peptides and NPRA gene expression are upregulated in states of pressure overload, we speculated that the effects of the natriuretic peptides on cardiac structure and function would be most apparent after pressure overload. To attenuate cardiomyocyte NPRA activity, transgenic mice with cardiac specific expression of a dominant-negative (DN-NPRA) mutation (HCAT D 893A) in the NPRA receptor were created. Cardiac structure and function were assessed (avertin anesthesia) in the absence and presence of pressure overload produced by suprarenal aortic banding. In the absence of pressure overload, basal and BNP-stimulated guanylyl cyclase activity assessed in cardiac membrane fractions was reduced. However, systolic blood pressure, myocardial cGMP, log plasma ANP levels, and ventricular structure and function were similar in wild-type (WT-NPRA) and DN-NPRA mice. In the presence of pressure overload, myocardial cGMP levels were reduced, and ventricular hypertrophy, fibrosis, filling pressures, and mortality were increased in DN-NPRA compared with WT-NPRA mice. In addition to their hormonal effects, endogenous natriuretic peptides exert physiologically relevant autocrine and paracrine effects via cardiomyocyte NPRA receptors to modulate cardiac hypertrophy and fibrosis in response to pressure overload.
authors.affiliation: Cardiorenal Research Laboratory, Guggenheim 9, Mayo Clinic, 200 First St., Southwest, Rochester, MN 55905, USA.
authors.forename: Jeetendra B
authors.initials: JB
authors.lastname: Patel
authors.forename: Maria L
authors.initials: ML
authors.lastname: Valencik
authors.forename: Allison M
authors.initials: AM
authors.lastname: Pritchett
authors.forename: John C
authors.initials: JC
authors.lastname: Burnett
authors.forename: John A
authors.initials: JA
authors.lastname: McDonald
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Redfield
mesh_terms: D000818:Animals; D001011:Aorta; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure; D006152:Cyclic GMP / Q000378:metabolism; D004452:Echocardiography; D015870:Gene Expression; D005799:Genes, Dominant; D006162:Guanylate Cyclase / Q000235:genetics / Q000378:metabolism*; D006973:Hypertension / Q000401:mortality* / Q000503:physiopathology*; D008026:Ligation; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D009154:Mutation; D009206:Myocardium / Q000378:metabolism*; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics / Q000378:metabolism*; D019076:Transgenes; D020257:Ventricular Remodeling
chemical_list: D009320:Atrial Natriuretic Factor; D006162:Guanylate Cyclase; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A; D006152:Cyclic GMP